TyRx, Inc. has launched the AIGISRX(TM) ICD, an anti-bacterial envelope designed to stabilize the implanted device and which also contains anti-microbial agents that protect against surgical site infections (SSI) associated with implantable cardioverter defibrillators (ICDs). Doctors insert the ICD into the AIGISRX during a CRMD implantation procedure and position the device within the pocket created by surgery. On being implanted, the anti-bacterial envelope provides an add-on to general antibiotic treatment. It elutes the anti-microbial agents rifampin and minocycline, thereby stabilizing the implanted ICD.